Calypso Biotech B.V.
Calypso Biotech B.V. is a biopharmaceutical spin-off company from Merck Serono specializing in the development of therapeutic antibodies against immune checkpoints to treat emerging severe pathologies. Calypso’s lead program, CALY-002, is a best in class antibody which binds to and neutralizes interleukin-15 (IL-15).
Calypso raised €20M in financing led by Gilde Healthcare to bring CALY-002 into the clinic for Eosinophilic Esophagitis (EoE). This is an emerging immune pathology driven by food antigens, resulting in severe dysphagia and poor quality of life in children and adults. With more than 300 000 people living with EoE, and no approved biologicals on the market today, a large unmet need for effective treatment exists.
Amsterdam, The Netherlands
and Geneva, Switzerland